10x Genomics (TXG) Reports In-Line Q1 EPS, provides guidance

10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.50), in-line with the analyst estimate of ($0.50). Revenue for the quarter came in at $141 million versus the consensus estimate of $142.24 million.

GUIDANCE:

10x Genomics sees FY2024 revenue of $670-690 million, versus the consensus of $677.8 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• The Gap, Inc. (GAP) Tops Q2 EPS by 3c
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance